Mineralys Therapeutics, Inc. (MLYS) Form 8-K — Oct 29, 2026

$MLYSForm 8-KItems 1.01, 1.02Filed Oct 29, 2026, 4:08 PM ET0001933414-26-000136Original filing

Mineralys Therapeutics and Tanabe Pharma Corporation entered into a Termination Agreement on October 27, 2026, ending the July 2020 license agreement and assigning all lorundrostat patents and know-how directly to Mineralys.

Key figures

Change of control payment: $100.0 million
Commercial milestones first indication: $255.0 million
Commercial milestones second indication: $10.0 million

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.